{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"iTeos Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ITOS"},"Address":{"label":"Address","value":"321 ARSENAL STREET, WATERTOWN, Massachusetts, 02472, United States"},"Phone":{"label":"Phone","value":"+1 339 217-0161"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody."},"CompanyUrl":{"label":"Company Url","value":"https://www.iteostherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Feltquate","title":"Chief Medical Officer"},{"name":"Katie George","title":"Executive Director-Clinical Operations"},{"name":"Matthew A. Call","title":"Chief Operating Officer"},{"name":"Michel Detheux","title":"President, Chief Executive Officer & Director"},{"name":"Yvonne McGrath","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}